‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose
Eli Lilly has announced a new gene-editing therapy, VERVE-102, which can reduce LDL cholesterol by up to 62% with a single dose. The treatment works by turning off the PCSK9 gene, which is responsible for regulating cholesterol levels in the liver. Preliminary results from a small trial show promising outcomes, with no serious adverse effects reported.
- ▪VERVE-102 can lower LDL cholesterol by up to 62% with just one infusion.
- ▪The treatment has shown lasting effects, with results still evident in some participants 18 months later.
- ▪A Phase 2 clinical study of VERVE-102 is expected to begin by the end of the year.
Opening excerpt (first ~120 words) tap to expand
Health ‘Revolutionary’ new treatment can lower bad cholesterol by up to 62% — with just one dose By Rachel Sacks Published May 26, 2026, 2:29 p.m. ET See more of our coverage in your search results. Add The New York Post on Google One and done? Pharma giant Eli Lilly announced Monday that its gene-editing therapy can reduce LDL (“bad”) cholesterol by up to 62% with a single infusion. Not only was the experimental treatment successful, but the results were still apparent in some participants 18 months after they received the dose. VERVE-102 may be a revolutionary treatment for bad cholesterol before it leads to heart disease.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
